

17 September 2024

ASX Announcement

Cleansing Notice pursuant to Share Purchase Plan

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) gives this notice pursuant to *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/ 547 (Instrument)*.

The Company will make offers to issue fully paid ordinary shares (**Shares**) under a share purchase plan (announced to ASX on 12 September 2024) without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Corporations Act**).

In accordance with the Instrument, the Company confirms that:

1. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 and section 674A of the Corporations Act; and
2. as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

This announcement has been approved for release to the ASX by the Board of Firebrick Pharma Ltd.

- ENDS -

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.